Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticlePediatric Rheumatology

Incidence of Wegener’s Granulomatosis in Children

SILVIU GRISARU, GILBERT W.H. YUEN, PAIVI M. MIETTUNEN and LORRAINE A. HAMIWKA
The Journal of Rheumatology February 2010, 37 (2) 440-442; DOI: https://doi.org/10.3899/jrheum.090688
SILVIU GRISARU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GILBERT W.H. YUEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAIVI M. MIETTUNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LORRAINE A. HAMIWKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To determine the incidence and longitudinal trends of Wegener’s granulomatosis (WG) in the pediatric population of Southern Alberta over the last 15 years.

Results. Fifteen cases of childhood WG were confirmed. The average annual incidence was 2.75 cases/million/year, with a steep increase over the last 5 years to 6.39 cases/million/year.

Conclusion. In Southern Alberta the incidence of childhood WG during the past 15 years was comparable to the incidence reported in adults and it seems to be increasing. Further studies are required to determine if this is a regional or global phenomenon.

Key Indexing Terms:
  • WEGENER’S GRANULOMATOSIS
  • CHILDREN
  • INCIDENCE

Wegener’s granulomatosis (WG) is a systemic inflammatory disease that causes necrotizing vasculitis of small vessels. Classically, it affects the upper and lower respiratory tract as well as the kidneys. Detection of antineutrophil cytoplasmic antibodies (ANCA), in particular the cytoplasmatic form (c-ANCA), has been closely associated with WG1. The etiology of WG is unknown but staphylococcus infections and exposure to silica have been postulated as potential triggers2. The incidence of WG in the adult population has been well documented, with reported incidences ranging from 3 to 14 cases/million/year3–5. WG has been historically considered a disease of adults with very rare occurrence in the pediatric population6. Consequently, there have been no published reports on the incidence of WG in children except 1 from northern Sweden that included young adults (18–30 years of age), reporting an incidence of 0.5 cases/million per year7. The objectives of our study were to determine the incidence of childhood WG and to identify changing trends in the incidence of this disease over the last 15 years in a well defined pediatric population.

MATERIALS AND METHODS

Calculation of childhood WG incidence in Southern Alberta was based on the definition of Southern Alberta as the catchment area for the Alberta Children’s Hospital (ACH) in Calgary and validation of WG cases by a chart review of patients identified after searching all ACH inpatient and outpatient electronic databases from March 1993 onward.

The ACH is the sole tertiary-care pediatric referral center for 1.6 million inhabitants of Southern Alberta, Canada. Peripheral general hospitals provide limited pediatric care and all children requiring pediatric subspecialty attention are referred to the ACH or are managed by ACH physicians in outreach outpatient clinics. The catchment area served by the ACH during the study period was accurately defined by the regional health care administration system used in Alberta. Census-derived, regional, age-specific annual population statistics were obtained from Statistics Canad7a and the Alberta government7b.

ACH databases containing outpatient and inpatient diagnosis data were queried from March 1993 onward using International Classification of Diseases (ICD9) and ICD10 codes for Wegener’s granulomatosis, polyarteritis nodosa, Churg-Strauss, microscopic polyangiitis, and other necrotizing vasculopathies. The following free text search terms were also used: vasculitis, ANCA, antineutrophil, and Wegener. This search strategy identified all patients who had these diagnoses/terms mentioned in their inpatient or outpatient charts at any time since their presentation. Identifying patients who may have fulfilled criteria for WG but were never diagnosed or suspected as such was beyond the scope of our study.

Charts of identified patients were then reviewed for validation of WG diagnosis and data collection.

Inclusion criteria were (1) age at presentation younger than 18 years; (2) available documentation in the patient’s chart sufficient to satisfy the WG diagnostic criteria of the American College of Rheumatology8 or the European League Against Rheumatism/Paediatric Rheumatology European Society (EULAR/PReS)9; and (3) residence in the region for at least 5 years.

Exclusion criteria were insufficient documentation for validation of WG diagnosis, and patient/family refusal to be included in the study.

StatsDirect® 2.7.0 (StatsDirect Ltd., Altrincham, UK) software was used for statistical analysis; graphs were generated with SigmaPlot® 2.01. The average incidence of WG during the first 10 years of the study was compared to the incidence in the last 5 years using a chi-square analysis. Graphic representations of the absolute number of cases and the 3-year moving average of WG annual incidences among children in Southern Alberta were created.

Ethical approval was granted by the University of Calgary Research Ethics Board (E-21562).

RESULTS

Thirty-two patients were identified but only 15 met the inclusion criteria. Excluded patients were eventually diagnosed with the following diseases: 3 systemic lupus erythematosus, 1 Henoch-Schönlein purpura, 1 IgA nephropathy, 1 Kawasaki disease, and 1 juvenile dermatomyositis. Nine additional patients had various rashes that were suspected to represent vasculitis at presentation but eventually resolved without specific intervention and remained undiagnosed. The remaining patient of the excluded 17 had a diagnosis of suspected Wegener’s based on chest imaging studies demonstrating diffuse nodular lesions with granulomas on histology. However, the pulmonary lesions disappeared without specific treatment, ANCA levels were never elevated, and no other systemic involvement was demonstrated.

Demographic and clinical characteristics of included patients are summarized in Table 1. The average age at presentation was 12.7 years, with no significant gender difference.

View this table:
  • View inline
  • View popup
Table 1

Demographic and clinical characteristics of children diagnoses with Wegener’s granulomatosis in Southern Alberta in the last 15 years.

The overall average annual incidence of childhood WG in Southern Alberta over the last 15 years was 2.75 cases/million/year (95% CI 1.93–3.70). During the first 10 years of this period (1994–2003), the average incidence was only 0.93 cases/million/year (95% CI 0.41–1.70); however, during the past 5 years (2004–2008) it reached 6.39 cases/million/year (95% CI 4.37–9.03). A chi-square analysis comparing the average annual incidences in these 2 periods yielded a significant p value of 0.00402.

The absolute numbers of childhood WG cases are shown in Figure 1, while the 3-year moving average of WG annual incidences among children in Southern Alberta is illustrated in Figure 2.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

. Absolute numbers of childhood Wegener’s granulomatosis cases in Southern Alberta.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

. The 3-year moving average of Wegener’s granulomatosis annual incidences among children in Southern Alberta.

DISCUSSION

This is a first population-based report on the incidence of childhood WG in Southern Alberta, demonstrating that the incidence of this disease there over the last 15 years was comparable to the incidence previously reported in adults3–5. In addition, a steep increase in the incidence of childhood WG in Southern Alberta, particularly during the last 5 years, was observed. Increasing incidence of WG among adults has been reported10,11. The results of this report support a similar observation in children.

We believe that these findings represent a real increase in incidence rather than improved recognition of childhood WG. Tests of serum levels of antineutrophil cytoplasmic antibodies (anti-PR3 and anti-MPO) have been readily available during the entire study period and we have not identified major changes in the diagnostic approach to suspected vasculitides during the study period at our center. Southern Alberta’s population increased significantly during the study period, with a disproportional advantage toward urban population growth. Previous reports found vasculitides in general to be more prevalent in urban areas12.

A thorough review of our cohort characteristics has not identified any previously published risk factors for WG such as exposure to infections or farming products2. Nevertheless, while searching for potential environmental factors associated with WG, we found that drinking water fluoridation was introduced in our region in 1991 after a plebiscite. This may be of interest, because the product used to increase fluoride levels of the water supply in our region is hydrofluorosilicate (H2SiF6), which dissociates thoroughly into free fluoride and silicate that can polymerize into stable colloidal silica at neutral pH13,14. Studies have suggested that exposure to silica may be a potential trigger for WG2,15.

Clearly, any correlation between exposure to silica in drinking water and WG is highly speculative; however, we believe it deserves further attention, particularly in view of the well documented regional variability in the prevalence of WG16.

We conclude that in Southern Alberta the average incidence of childhood WG is comparable to the reported incidence in adults, due mostly to a significant increase in the last 5 years. Retrospective and prospective surveillance studies from other regions in Canada and the rest of the world are required to clarify if our observation represents a regional or global phenomenon.

Footnotes

    • Accepted for publication September 21, 2009.

REFERENCES

  1. 1.↵
    1. Kallenberg CGM,
    2. Heeringa P,
    3. Stegeman CA
    . Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661–70.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. de Lind van Wijngaarden RA,
    2. van Rijn L,
    3. Hagen EC,
    4. Watts RA,
    5. Gregorini G,
    6. Tervaert JW,
    7. et al.
    Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008;3:237–52.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Watts RA,
    2. Scott DGI,
    3. Lane SE
    . Epidemiology of Wegener’s granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. Cleve Clin J Med 2002;69 Suppl:SII84..
  4. 4.↵
    1. Lane SE,
    2. Watts RA,
    3. Scott DG
    . Epidemiology of systemic vasculitis. Curr Rheumatol Rep 2005;7:270–5.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mahr AD,
    2. Neogi T,
    3. Merkel PA
    . Epidemiology of Wegener’s granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol 2006;24 Suppl:S82–91.
    OpenUrlPubMed
  6. 6.↵
    1. Hall SL,
    2. Miller LC,
    3. Duggan E,
    4. Mauer SM,
    5. Beatty EC,
    6. Hellerstein S
    . Wegener granulomatosis in pediatric patients. J Pediatr 1985;106:739–44.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Stegmayr BG,
    2. Gothefors L,
    3. Malmer B,
    4. Müller Wiefel DE,
    5. Nilsson K,
    6. Sundelin B
    . Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol 2000;14:208–13.
    OpenUrlCrossRefPubMed
  8. 7a.
    Statistics Canada[Internet Accessed December 8, 2009. ] Available from: www12.statcan.gc.ca/census-recensement/index-eng.cfm.
  9. 7b.
    Alberta Health and Wellness. [Internet. Accessed December 8, 2009.] Available from: www.health.alberta.ca/documents/Trends-2000-demographics.pdf; <http://www.health.alberta.ca/documents/Trends-2000-demographics.pdf; and www.health.alberta.ca/documents/Population-Projections-2006.pdf.
  10. 8.↵
    1. Leavitt RY,
    2. Fauci AS,
    3. Bloch DA,
    4. Michel BA,
    5. Hunder GG,
    6. Arend WP,
    7. et al.
    The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–7.
    OpenUrlPubMed
  11. 9.↵
    1. Ozen S,
    2. Ruperto N,
    3. Dillon MJ,
    4. Bagga A,
    5. Barron K,
    6. Davin JC,
    7. et al.
    EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936–41.
    OpenUrlAbstract/FREE Full Text
  12. 10.↵
    1. Knight A,
    2. Ekbom A,
    3. Brandt L,
    4. Askling J
    . Increasing incidence of Wegener’s granulomatosis in Sweden, 1975–2001. J Rheumatol 2006;33:2060–3.
    OpenUrlAbstract/FREE Full Text
  13. 11.↵
    1. Watts RS,
    2. Mooney J,
    3. Lane SE,
    4. Scott DGI
    . Rheumatoid vasculitis: becoming extinct?. Rheumatology 2004;43:920–3.
    OpenUrlAbstract/FREE Full Text
  14. 12.↵
    1. Scott DGI,
    2. Watts RS
    . Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis 2000;59:161–3.
    OpenUrlFREE Full Text
  15. 13.↵
    1. Urbansky ET,
    2. Schock MR
    . Can fluoridation affect lead (II) in potable water? Hexafluorsilicate and fluoride equilibria in aqueous solution. Intl J Envir Studies 2000;57:597–637.
    OpenUrlCrossRef
  16. 14.↵
    1. Finney WF,
    2. Wilson E,
    3. Callender A,
    4. Morris MD,
    5. Beck LW
    . Reexamination of hexafluorosilicate hydrolysis by 19F NMR and pH measurement. Envir Sci Tech 2006;40:2572–7.
    OpenUrlCrossRef
  17. 15.↵
    1. Hogan SL,
    2. Cooper GS,
    3. Savitz DA,
    4. Nylander-French LA,
    5. Parks CG,
    6. Chin H,
    7. et al.
    Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2007;2:290–9.
    OpenUrlAbstract/FREE Full Text
  18. 16.↵
    1. Cotch MF,
    2. Hoffman GS,
    3. Yerg DE,
    4. Kaufman GI,
    5. Targonski P,
    6. Kaslow RA
    . The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996;39:87–92.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 2
1 Feb 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Incidence of Wegener’s Granulomatosis in Children
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Incidence of Wegener’s Granulomatosis in Children
SILVIU GRISARU, GILBERT W.H. YUEN, PAIVI M. MIETTUNEN, LORRAINE A. HAMIWKA
The Journal of Rheumatology Feb 2010, 37 (2) 440-442; DOI: 10.3899/jrheum.090688

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Incidence of Wegener’s Granulomatosis in Children
SILVIU GRISARU, GILBERT W.H. YUEN, PAIVI M. MIETTUNEN, LORRAINE A. HAMIWKA
The Journal of Rheumatology Feb 2010, 37 (2) 440-442; DOI: 10.3899/jrheum.090688
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • A Population-based Study of Grade 12 Academic Performance in Adolescents With Childhood-onset Chronic Rheumatic Diseases
  • Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus
  • Variations in Pediatric Rheumatology Workforce and Care Processes Across Canada
Show more Pediatric Rheumatology

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire